Skip to main content

Table 2 Associations between FFAs concentration and GDMb

From: Association of free fatty acid in first trimester with the risk of gestational diabetes mellitus: a nested case-control study

FFA

GDM (N = 50)

Control (N = 100)

OR(95%CI)

Pc

SFAa

    

C4:0

0.13 (0.10, 0.28)

0.14 (0.06, 0.24)

4.19 (0.24, 72.21)

0.315

C6:0

1.45 (1.13, 1.84)

0.93 (0.55, 1.63)

1.25 (0.85, 1.82)

0.244

C8:0

4.74 (4.04, 5.16)

2.46 (0.44, 4.87)

1.42 (1.14, 1.76)

0.003

C10:0

1.96 (1.54, 2.24)

1.46 (0.72, 2.13)

2.02 (1.10, 3.72)

0.024

C11:0

0.21 (0.14, 0.30)

0.27 (0.13, 0.57)

0.08 (0.01, 0.50)

0.009

C12:0

9.60 (7.28, 13.18)

8.33 (6.59, 10.36)

1.05 (0.97, 1.15)

0.224

C13:0

0.46 (0.27, 0.51)

0.51 (0.25, 0.92)

0.26 (0.07, 0.92)

0.037

C14:0

107.94 (86.66, 136.23)

98.30 (77.40, 131.82)

1.00 (0.99, 1.01)

0.615

C15:0

21.46 ± 5.09

20.49 ± 5.44

1.02 (0.95, 1.10)

0.588

C16:0

3648.64 (3289.18, 4093.15)

3741.44 (3270.67, 4588.65)

1.00 (1.00, 1.00)

0.256

C17:0

27.99 ± 5.60

27.33 ± 6.07

1.01 (0.94, 1.08)

0.763

C18:0

1023.17 (946.67, 1158.01)

1075.37 (941.64, 1690.35)

1.00 (1.00, 1.00)

0.073

C20:0

21.13 (19.21, 22.43)

20.85 (18.33, 24.28)

0.99 (0.91, 1.08)

0.819

C21:0

1.77 ± 0.43

1.73 ± 0.36

1.33 (0.49, 3.65)

0.569

C22:0

33.50 (29.41, 38.48)

35.41 (29.96, 40.30)

0.99 (0.95, 1.04)

0.784

C23:0

12.81 (10.75, 13.97)

13.41 (11.66, 15.42)

0.87 (0.77, 1.00)

0.048

C24:0

25.81 (23.78, 29.95)

25.89 (22.24, 31.18)

0.98 (0.93, 1.04)

0.475

MUFAa

    

C14:1

3.58 (2.43, 5.22)

2.54 (1.72, 3.65)

1.23 (1.04, 1.46)

0.015

C15:1

2.08 (1.47, 3.03)

1.41 (0.71, 2.91)

1.16 (0.83, 1.62)

0.378

C16:1

163.31 (132.29, 201.84)

134.67 (106.67, 163.86)

1.01 (1.00, 1.02)

0.023

C17:1

9.12 (7.04, 11.09)

7.86 (6.62, 9.78)

1.07 (0.94, 1.23)

0.290

C18:1 cis-n9

1321.75 ± 221.88

1237.22 ± 222.55

1.00 (1.00, 1.00)

0.067

C20:1

26.11 (21.59, 30.47)

20.06 (11.91, 28.20)

1.06 (1.01, 1.12)

0.019

C22:1n9

19.89 (18.52, 20.92)

19.37 (18.20, 20.55)

0.96 (0.79, 1.16)

0.647

C24:1

47.44 ± 10.44

51.19 ± 13.31

0.96 (0.92, 0.99)

0.021

PUFAa

    

C18:2 cis-n6

2905.56 ± 459.26

2710.16 ± 438.90

1.00 (1.00, 1.00)

0.065

C18:3n6

26.46 (13.03, 39.86)

19.78 (12.20, 32.46)

1.03 (1.00, 1.06)

0.025

C18:3n3

91.65 (75.75, 110.36)

78.76 (63.04, 101.80)

1.01 (1.00, 1.02)

0.169

C20:2

29.93 ± 8.21

27.59 ± 7.68

1.03 (0.98, 1.08)

0.226

C20:3n6

132.49 (101.08, 157.34)

108.27 (81.82, 144.06)

1.01 (1.00, 1.02)

0.044

C20:3n3

2.93 (2.37, 3.93)

2.60 (1.95, 3.45)

1.21 (0.88, 1.67)

0.230

C20:4n6

544.71 ± 142.42

505.48 ± 139.99

1.00 (1.00, 1.01)

0.149

C22:2

3.12 (2.56, 4.29)

2.85 (2.50, 3.84)

1.20 (0.86, 1.68)

0.279

C20:5n3

75.74 (56.48, 115.34)

57.12 (34.58, 92.37)

1.01 (1.00, 1.02)

0.028

C22:6n3

439.67 (388.11, 517.04)

372.30 (278.76, 481.00)

1.00 (1.00, 1.01)

0.015

TFAa

    

C18:1 trans-n9

6.98 (4.37, 11.27)

9.61 (6.51, 18.97)

0.91 (0.85, 0.98)

0.015

C18:2 trans-n6

1.01 (0.68, 1.81)

0.99 (0.55, 1.40)

1.17 (0.67, 2.04)

0.578

  1. a Multiple imputation was performed on the concentration of FFAs; b adjusted for exercise after pregnancy, weight gain from pregnancy to gestational age of week 24, diabetes history, carbohydrate intake frequency score, protein intake frequency score, fiber intake frequency score, and supplement intake ; cP was obtained through conditional logistic regression
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us